The Indian government has responded decisively to the crisis of child deaths linked to a toxic cough syrup by mandating enhanced testing protocols across the nation. The Directorate General of Health Services has issued a directive to all states and Union Territories, emphasizing the critical need for robust batch testing of pharmaceutical ingredients and finished products. This initiative requires strict compliance with safety regulations and the exclusive use of ingredients from approved suppliers. The urgency behind this directive is underscored by the discovery of diethylene glycol (DEG) contamination in a cough syrup at levels 500 times higher than permitted, a finding that tragically resulted in numerous child fatalities and critical illnesses. This comprehensive regulatory push is a vital step in safeguarding public health and ensuring drug safety.
